Skip to main content
eScholarship
Open Access Publications from the University of California

Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2

  • Author(s): Light, GA
  • Swerdlow, NR
  • Thomas, ML
  • Calkins, ME
  • Green, MF
  • Greenwood, TA
  • Gur, RE
  • Gur, RC
  • Lazzeroni, LC
  • Nuechterlein, KH
  • Pela, M
  • Radant, AD
  • Seidman, LJ
  • Sharp, RF
  • Siever, LJ
  • Silverman, JM
  • Sprock, J
  • Stone, WS
  • Sugar, CA
  • Tsuang, DW
  • Tsuang, MT
  • Braff, DL
  • Turetsky, BI
  • et al.
Abstract

© 2013. Mismatch negativity (MMN) and P3a are auditory event-related potential (ERP) components that show robust deficits in schizophrenia (SZ) patients and exhibit qualities of endophenotypes, including substantial heritability, test-retest reliability, and trait-like stability. These measures also fulfill criteria for use as cognition and function-linked biomarkers in outcome studies, but have not yet been validated for use in large-scale multi-site clinical studies. This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study. The extent to which demographic, clinical, cognitive, and functional characteristics contribute to variability in MMN and P3a amplitudes was also examined. Participants (HCS n. =. 824, SZ n. =. 966) underwent testing at 5 geographically distributed COGS laboratories. Valid ERP recordings were obtained from 91% of HCS and 91% of SZ patients. Highly significant MMN (d. =. 0.96) and P3a (d. =. 0.93) amplitude reductions were observed in SZ patients, comparable in magnitude to those observed in single-lab studies with no appreciable differences across laboratories. Demographic characteristics accounted for 26% and 18% of the variance in MMN and P3a amplitudes, respectively. Significant relationships were observed among demographically-adjusted MMN and P3a measures and medication status as well as several clinical, cognitive, and functional characteristics of the SZ patients. This study demonstrates that MMN and P3a ERP biomarkers can be feasibly used in multi-site clinical studies. As with many clinical tests of brain function, demographic factors contribute to MMN and P3a amplitudes and should be carefully considered in future biomarker-informed clinical studies.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View